Preclinical

A 2026 review in International Journal of Molecular Sciences (Yuan et al., MDPI) confirms BPC-157 operates across two mechanistically distinct axes simultaneously: a regenerative axis driven by angiogenesis, collagen synthesis, and fibroblast activation, and an analgesic axis mediated through nitric oxide modulation and dopaminergic–opioid system interactions. Both axes are documented exclusively in preclinical models; no human RCT data exists.

BPC-157 dose- and time-dependently increases growth hormone receptor (GHR) expression in tendon fibroblasts at both mRNA and protein levels — documented by Chang et al. (2014, Molecules) and reaffirmed in the 2026 Matek review. The mechanism amplifies GH-axis signaling locally in tendon tissue, sensitising fibroblasts to circulating GH without raising systemic GH output.

A 2025 narrative review published in Current Reviews in Musculoskeletal Medicine (Springer) concludes that BPC-157 drives robust preclinical regeneration across tendon, ligament, muscle, and bone via at least three distinct molecular pathways — yet zero human RCTs exist, and its angiogenic signaling raises unresolved oncogenic questions that performance athletes and practitioners cannot currently quantify.